text:
Manchester chief on alderman's allegations: 'He was deemed to be lying'By BILL SMITH
New Hampshire Union Leader
February 15. 2014 10:59PM
MANCHESTER - Police Chief David Mara says it came as no surprise that the Attorney General's Office found allegations by Alderman-at-Large Joe Kelly Levasseur against his department to be "untruthful."
"We knew that what he was saying was false from the beginning, so I have no feeling of vindication," Mara said in a telephone interview Friday.
"We knew they were lies, we knew they were false accusations, I'm just happy the report came out and the citizens of Manchester can see what we knew all along."
Levasseur, a lawyer, says his allegations of intimidation of himself and a client were made in an email to Mara last summer because they involved Manchester personnel. One situation involved a confrontation he'd had with a union official after an aldermen meeting; the other involved the investigation of a Manchester patrolman accused of assaulting his client in Hooksett.
Mara turned over the matter to the Attorney General's Office.
On Friday, Levasseur said, "It's a masterful play by Mara to turn the issue on to me. They've been after me since I started the job four years ago."
In an email to Mara last summer, Levasseur alleged the following: that Steve Maloney, president of the city police union, tried to intimidate him as an elected city official; that another civilian employee of the department intimidated Levasseur; and that Maloney has tried to interfere with the investigation in Hooksett.
After an investigation, Foster said the allegations were "unfounded." An unattributed "executive summary" of the findings distributed by the Attorney General's Office referred to Levasseur as "untruthful," a word that does not appear in Foster's official report.
"He was deemed to be lying, being untruthful, in making stories up, that is what this is about," Mara said. "He claims he got threatened by a Manchester police employee during a Board of Aldermen meeting, it didn't happen; he claimed the union president assaulted him, it didn't happen; he claims that the Manchester Police Department has been intimidating him, it didn't happen. All the things he said happened did not happen."
Levasseur refused to back away from the allegations Friday.
"My perception of the event is they were trying to intimidate me," Levasseur said. "My perception at the time is my perception to this day."
Manchester police officers have been ordered to bring a second officer into any interaction with Levasseur.
"We just have to be careful. When they are dealing with him, there have to be at least two people there," Mara said. "He's accused several people in the department of wrongdoing; it's a standing order, this is a very unique situation."
Levasseur maintains he asked Mara to look into the allegations because he believed Manchester officers were intimidating his client in the aftermath of a complaint she made last July against Patrolman William Soucy. In that case, Soucy was arrested on a misdemeanor assault charge stemming from the incident, which allegedly occurred in Hooksett. The case is still pending.
"I'm a big boy, they can come after me," Levasseur said. "But this was textbook intimidation of a client."
Mara suggested that Levasseur should not be in a position where he cross-examines Manchester police officers in courtrooms. "If you're an elected official, you make decisions affecting police and you vote on issues, and then you cross-examine a police officer," said Mara, who is also an attorney. "I think that is an inherent conflict."
Neither Mara nor Lavasseur plans on doing much differently as a result of Foster's findings.
Levasseur said he will pursue the Hooksett case, for which he said he is not being paid, to its conclusion.
"I'm the only guy in the world who would help her," he said. "This is the price I pay for helping."
Mara said the report won't change the way the department is run.
"It doesn't change anything. I am going to continue to be professional and to do my job; I have an obligation to the people of Manchester," Mara said. "My officers are going to continue to do their job protecting the citizens of Manchester."
Several aldermen declined to comment on the attorney general's findings, but former Alderman Phil Greazzo, who had feuded with Levasseur while in office, said he thought the matter should be referred to the city Public Conduct Board. The board was established to investigate malfeasance by city officers.
"I believe his conduct falls under sections of the charter that allow the aldermen to remove him,'' Greazzo said.
Mayor Ted Gatsas said only that the attorney general's "report speaks for itself.''
As an attorney, Levasseur is subject to the Code of Professional Conduct for attorneys. The ethics code states that it is professional misconduct to "engage in conduct involving dishonesty, fraud, deceit or misrepresentation."
The Attorney General's Office won't say whether it has any plans to present its findings to the Committee on Professional Conduct, which has the authority to investigate attorneys and recommend sanctions.
Assistant Attorney General Benjamin Agati refused to say whether Foster will make a formal complaint to the committee.
"We recognize our professional obligation," Agati said.
Janet Devito, general counsel to the committee, said a signed formal complaint, verified by a notary public or justice of the peace, is needed to proceed with a formal investigation of a complaint.
It is unclear what weight, if any, Foster's findings might have if the Professional Conduct Committee was to receive such a verified complaint concerning Levasseur's actions in the police controversy.
The report Foster issued is not the product of a formal proceeding in which Levasseur could confront witnesses against him.


text:
Biotech Boulevard
Ablexis is a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for the efficient discovery and development of the next wave of human therapeutic antibodies. Ablexis is commercializing the AlivaMab Mouse platform through partnering strategies that provide broad, non-exclusive access with no target or field-of-use restrictions.
Accera is a privately-held, commercial-stage, healthcare company focused on the discovery, development and in-licensing of innovative therapeutics to treat Central Nervous System (CNS) disorders.
Adynxx is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Afraxis is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. PAK is also implicated in cancer, including Neurofibromatosis, a rare form of cancer for which there are no approved drugs. Inhibiting PAK activity has the potential to induce significant anti-tumor activity.
Alcresta is developing and commercializing innovative enzyme-based nutritional products that improve patient health and manage disease for infants, older adults and patients battling acute or chronic conditions. Leveraging its existing proprietary platform of nutritional products and medical devices, Alcresta has developed a lead program designed to improve the delivery, digestion and absorption of long-chain polyunsaturated fatty acids (including omega-3 and omega-6) to support pediatric growth and development, help strengthen the immune system, accelerate the recovery of patients battling acute or chronic conditions, and enhance active adult nutrition.
AliveCor aims to provide medical professionals, patients (be they human or animal), and consumers worldwide with mobile-powered devices, data, and analysis to identify, prevent, and treat life-altering diseases from anywhere in the world. As a first offering, AliveCor has developed a clinical-quality, low-cost ECG recorder that enables patients to monitor their heart health anywhere, at any time and provides physicians with a more comprehensive assessment. The AliveCor smartphone ECG is designed to work in conjunction with a variety of mobile platforms, including iPhone, iPad, and Android devices.
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The company was founded in 2011 by industry leaders with a proven track record of success in protein therapeutic design and development. Allena is leveraging its leadership team's combined operational expertise in manufacturing, formulation and non-systemic protein delivery.
AMSilk is the first company to manufacture spider silk, a high performance protein that can be used for medical devices, wound healing, pharmaceutical products and fibers. The company's unique biotechnological process, invented at the Technische Universität München, has been scaled to industrial size for ton-scale production. AMSilk's spider silk retains the performance properties of natural spider silk, is biocompatible and can be processed into films, coatings, foams, nonwovens and fibers. AMSilk is developing several wound treatments and technical fibers (Biosteel® ) for medical and ballistic textiles.
Apexigen is a biotherapeutic development company advancing antibody drug candidates for the treatment of cancer and other serious diseases. The pipeline is led by APX005, an antibody that both exerts direct anti-tumor actions and activates an anti-tumor immune response. Four other product candidates are currently under development through collaborations. The company's proprietary rabbit-derived humanized antibody technology platform enables the discovery of a broad diversity of antibodies to a target antigen. This great diversity of antibodies enables the discovery of antibodies with rare or specific biological properties, which may become the next generation of breakthrough therapeutics. Apexigen is employing its strategy to develop innovative bio-therapeutics, advance its product pipeline, and see that important new therapies are made available to patients.
Based on its aptamer technology platforms, Aptamer Sciences Inc. is a privately held biotech company focused on commercializing technologies for analysis of proteins. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics.
Aratana Therapeutics licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and develops strategies to maximize the value of the programs. The company is developing novel compounds to address unmet and under-served medical needs in in companion animal care including pain, cachexia, and frailty. These compounds are supported by substantial safety and effectiveness data and will represent best- or first-in-class products in the animal health industry.
Array Bridge provides products and services that address two important areas in the development of biologics: biosimilar drug comparability analysis and impurity analysis. Array Bridge has developed "antibody arrays" to measure biosimilar drug comparability at the molecular level, providing a measurement of biosimilar conformational comparability. This antibody array-based technology can be used at all stages of biosimilar development, from cell line selection and process development to clinical testing and product release. For impurity analysis, the company provides ELISA kits and reagents for Host Cell Protein quantitation and Western Blot analysis.
Asthmapolis is dedicated to improving the management of asthma for patients and healthcare professionals. It uses medication sensors, mobile applications, advanced analytics and feedback to help physicians identify those patients who need more help controlling the disease.
Avia Biosystems' products provide solutions to common bottlenecks that limit the development and formulation of biologics. The first product developed by the company, the fluorescence-based Model 2304 Fully Automated Protein Denaturation System, automates protein stability studies, with primary applications in stability testing of protein constructs during discovery and development and biologics formulation stability testing during pre-clinical and clinical development. The system automatically prepares samples and the requested array of buffer and excipient conditions, collects fluorescence data, and processes the data for up to 96 protein samples or formulations.
Base Pair Biotechnologies is a spin-off of parent company BioTex, a developer of several molecular biology and diagnostic technologies. Scientists at Base Pair Bio have been studying aptamers and developing them on a research basis and offer these services commercially.
Bina is the big data science platform for large scale secondary and tertiary genomic analysis. Bina uses big data and cloud technologies to process raw genetic data in order to help clinicians and researchers administer treatment based on an individual's unique DNA. Bina's mission is to accelerate personalized medicine using whole genome analysis. The company was founded in 2011 by a team of Stanford and Berkeley researchers, data scientists, bioinformaticians, and entrepreneurs.
BioLamina is a rapidly expanding biotechnology company within the stem cell and cell differentitation fields. Started as recently as 2009, it is already acknowledged as one of Sweden's 33 most promising young technology companies. BioLamina produces and sells high-quality human recombinant laminins that are the foundation on which cells grow in vivo – and most likely the optimal surface for stem cells, primary cells and cell differentiation in vitro.
BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to increase efficacy whilst reducing side effects. MOTI1001 is BioMoti's lead Oncojan™ based ovarian cancer candidate. Oncojans are a new class of therapeutic microparticles that can target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
BioTillion is enhancing the way samples are tracked in low temperature biobanks using RFID technology. They enable real-time precision tracking of samples in situ.
Blueprint Medicines is committed to improving the lives of cancer patients by transforming genomically-defined subsets of cancer from life-threatening diseases to manageable conditions. Blueprint Medicines is harnessing the potential of the cancer genomics revolution by rapidly translating emerging insights into impactful drug programs.
BlueSEQ helps research labs, universities, hospitals, and genome centers around the world design and outsource next-generation sequencing projects. The company matches sequencing service needs with providers that have the right next-generation sequencing technology and expertise. BlueSEQ provides a neutral source of market and technical information to support optimal next-generation sequencing project design and service provider compatibility.
Cardeas is a privately held pharmaceutical company dedicated to the development and commercialization of inhaled antibiotics to treat serious, hospital-acquired respiratory infections with highly antibiotic-resistant organisms. By combining novel formulations of proven antibiotics with cutting edge drug delivery technology, Cardeas is addressing significant unmet medical needs in the critical-care setting.
Cardio3 BioSciences is a biopharmaceutical company involved in the discovery, development, and commercialization of regenerative and protective therapies for cardiovascular diseases.The aim of these therapies is to protect the heart during myocardial injury, reduce the volume of the scar and reconstruct damaged heart tissue. The company's product candidates and research programs are based on the proprietary Cardiopoiesis technology platform, which is based on fundamental research conducted at Mayo Clinic.
Catabasis is a clinical stage company that develops products to target inflammatory, immunological and metabolic diseases. It's SMART linker platform technology produces new chemical entities that have amplified efficacy along a clinically validated disease pathway through the conjugation of two known products via a linker that is metabolized intracellularly in cells relevant to the particular disease.
Cellworks has built a pipeline of drug candidates for cancer and rheumatoid arthritis by implementing a novel approach to therapeutic design and development. The Cellworks approach combines a predictive and responsive network of protein interactions with sophisticated algorithms to emulate human physiology and predict clinical outcomes early on. The company is using this technology to design novel mechanism of actions by combining existing FDA approved drugs that work synergistically to impact multiple disease pathways simultaneously.
Cleave Biosciences is discovering and developing novel small molecule therapies for difficult-to-treat cancers by targeting protein homeostasis through the ubiquitin proteasome and autophagy systems, an area of unrealized potential. Cleave is using molecular profiling approaches with the goal of identifying patient subsets most likely to benefit from each of its targeted drugs.
Curiox Biosystems develops and commercializes cellular assay systems. Its first product, the DropArray™ platform, is intended to accelerate the progress of basic research, drug discovery and diagnostics through the miniaturization and automation of bioassays. The Curiox DropArray platform allows scientists to perform low-volume cellular assays efficiently using adherent, weakly adherent and even non-adherent cells, achieving long-term on-plate incubations without evaporation. Curiox recently introduced the LT210 (low throughput) or HT200 (high throughput) DropArray Washing Stations to automate the task of adding or changing media and buffers.
CytomX is a biotechnology company focused on improving the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's Probody™ Platform represents a transformational drug discovery and development approach for antibodies, enabling improved specificity, increased efficacy and decreased toxicity.
Dezima Pharma develops drugs to treat dyslipidemia, a major modifiable risk for cardiovascular disease. Its objective is to develop compounds from pre-clinical development to meaningful proof of concept in patients. Dezima will seek strategic partners to further development in the larger cardiovascular indications, and/or continue in-house development of its compounds in smaller, orphan-type indications. The Netherlands-based company was founded by Forbion Capital Partner and BioGeneration Ventures.
Dynamic Biosensors develops and commercializes the proprietary switchSENSE technology for molecular interaction analysis. In addition to binding affinity and kinetics, the dynamic character switchSENSE allows to determine molecular size, conformational changes, charge, and certain post-translational modifications of the target in the same measurement. Dynamic Biosensors is a spin-off of the Technische Universität München.
eADMET is an expert in the creation of customized computational models for the prediction of important ADME/Tox properties of small drug-like molecules. The company's modular approach combines proprietary and selected external algorithms to inform the creation of customized prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.
Elcelyx Therapeutics is a privately-held company developing products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. Elcelyx product candidates, Lovidia™ and NewMet™, are Gut Sensory Modulators backed by research and clinical data demonstrating their ability to rapidly reduce weight and improve glucose metabolism without systemic side effects, respectively.
Ember Therapeutics is a product-focused company translating its biology in the emerging area of brown fat and recent breakthroughs in understanding the mechanisms of selective insulin sensitivity into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity.
Envoy's mission is to change drug discovery by advancing new drugs that act on targets expressed specifically in the cell populations important to diseases. Their goal is to bring forth drugs that help millions of people while causing fewer side effects. Envoy hopes to achieve this mission through their powerful technology, called "bacTRAP", that allows them to measure, in vivo, the expression of each protein within any given cell type.
Eqalix is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing nano-materials for the repair and regeneration of diseased, traumatized, and aging tissues. The company plans to develop and commercialize a plant-protein based nano-fiber scaffold for use in consumer markets and as a human skin substitute; small-diameter hybrid vessels that foster the creation of a functional endothelium after implantations; and 3D tissue scaffolds with adjustable properties for organ and tissue replacement and repair.
Eudendron is a start-up company devoted to the discovery and development of a new generation of Kinase inhibitors in the area of oncology personalized medicine. The company's molecular design aims to develop safer and effective drugs able to overcome drug resistance. Eudendron's new generation of Kinase inhibitors will be the result of a drug process called KemKinase, which encloses molecular designs and in silico validation technology coupled to a Kinome-wide strategy, revealing at a very early stage the full spectrum of Kinase targets associated to the newly identified chemical classes.
Flexion Therapeutics discovers and develops innovative therapeutics for musculoskeletal disorders. In order to provide safe and effective products, they are merging novel pharmacology with local, sustained delivery of drug to the site of disease; an approach that aims to ensure lasting therapeutic effect and systemic safety.
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical product, FoundationOne™, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials.
Gamma Therapeutics is an early stage biotechnology venture developing solutions for cardiovascular disease risk assessment, biosurgical therapy and combat casualty care based upon the use of human biocompatible proteins, such as Gamma Prime Fibrinogen, responsible for the clotting mechanism in human blood. The product line includes its patent-pending flagship product, GammaCoeur™, a cardiovascular disease risk assessment assay; GammaSeal™, a patented, high strength surgical incision and wound healing sealant; Gammarin™, a patented anticoagulant blood thinner for use during and after surgery, and; GammaTF, a provisionally-patented fast-clotting hemostatic dressing for hemorrhage control.
Genea Stem Cells (GSC) develops disease-specific pluripotent and differentiated human cells for use in drug discovery and research. Based on the world's largest private bank of human embryonic stem cells (about 100 lines/30 diseases), GSC supplies application-ready, disease-affected and control differentiated cell types and works collaboratively with industry for custom-developed cell-based assay solutions in drug development. All of GSC's cell products are genetically unmodified human cells - the most accurate in vitro reflection of clinical conditions.
GigaGen envisions a future where doctors routinely use an immune "fingerprint" to help manage complex medical problems such as transplantation, autoimmune disease, and cancer. The GigaMune™ technology combines microfluidics, next-generation sequencing, and bioinformatics to digitize your immune system into an immune "fingerprint".
Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to improve the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options. The company's unique SHAPE Platform is enabling the discovery and development of small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits.
Gradalis is a privately-held, fully-integrated biotechnology company based in Dallas, Texas that is developing, manufacturing and commercializing drugs, vaccines, tools and diagnostics primarily in the area of cancer. The company has two platforms: one focused on personalized autologous vaccines and the other on bifunctional short hairpin RNA delivered via a proprietary lipoplex system. Recently-published data showed that FANG, the company's autologous tumor vaccine, showed significant survival benefit in patients with advanced disease for multiple types of cancer. Gradalis has its own state of the art GMP manufacturing facility, as well as a strategic partnership with Mary Crowley Cancer Research Centers for early stage clinical development of Gradalis products.
Helmedix, a start-up company from the ithree institute at the University of Technology Sydney, is a biopharmaceutical company developing therapies for autoimmune diseases based on peptides derived from a helminth parasite. Helmedix will be managed as a virtual company, based in Sydney, with research contracted to Dr Donnelly's team at the ithree institute.
Hepregen's mission is to translate the value of its technology platform to improve the safety and efficacy of drugs in development with greater economic efficiency and significant impact on patients' lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac™, into the drug-development pipeline of pharmaceutical and biotechnology companies. Hepregen's platform technology offers the potential to deliver a breakthrough technology for toxicity screening and a new platform for drug discovery.
HiberGene is developing a molecular diagnostic test for meningitis which can be used to test for the presence of the two most common forms of the disease, Meningococcus and Pneumococca. The test uses a rapid isothermal amplification platform allowing accurate results to be delivered in less than forty minutes. The company intends to develop a range of tests for a number of infectious human diseases including healthcare associated infections and sexually transmitted Infections.
Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative prophylactic and therapeutic vaccines. The Vaxwave® technology is a vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and build a robust product pipeline. Hookipa has recently moved into its BSL2 facility at the Campus Vienna Biocenter.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management.
JB Therapeutics, a clinical stage biopharmaceutical company, is developing JBT-101 a nanomolar cannabinoid agonist which activates the CB2 receptor present on immune cells and fibroblasts. Upon binding CB2, JBT-101 stimulates the production of specific lipid mediators (PGJ2, LXA4) which act to turn off inflammation and fibrosis. The product is a pharmaceutical capsule containing a pure synthetic derivative of THC with minimal blood brain barrier penetration. It is currently being developed as a potential disease modifying treatment for the orphan disease scleroderma.
Jounce Therapeutics is a private company launched in 2013 and based in Cambridge, Massachusetts. The company is dedicated to transforming the treatment of cancer by focusing on the discovery and development of first-in-class cancer immunotherapies designed to work not by treating a patient's tumor directly, but instead by harnessing the patient's immune system to seek out and attack cancerous cells and tumors.
Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer. Kancera is currently running two pharmaceutical development projects, one relating to solid tumors and one relating to leukemia. Through a subsidiary, Kancera also provides big pharma, mid-sized pharma and biotech companies with lead identification and optimization services such as high-throughput screening (HTS), fragment-based screening (FBS), assay development and medicinal chemistry.
KemPharm is a development stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company's primary efforts include the development of safer abuse resistant opioid pain relievers. The company's drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.
Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies for multiple cancer indications. Kite is advancing a portfolio of product candidates designed to leverage and enhance the patient's own immune system to fight tumor cells. These personalized immunotherapies are aimed at providing significant and durable clinical benefit in a wide range of tumor indications.
Kymab is a "platform to product" biopharmaceutical company engaged in the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.
LabMinds develops, manufactures and sells next generation solutions for laboratory challenges with a particular focus on combining advanced laboratory products with leading edge usability and network technologies. LabMinds' lead product, EasySolution, automates the ubiquitous process of solution preparation worldwide, combining features such as water purification, solid storage, solid dosing, weighing, stirring, temperature control, pH control, vacuum filtering, label printing and GMP/GLP adherence in one extremely usable solution.
LifeAssay Diagnostics manufactures medical and veterinary devices, specializing in in vitro diagnostic tests. They produce a wide range of diagnostic tests for government, NGO procurement, and for private use.
Meritage Pharma is committed to the development of prescription products for the treatment of gastrointestinal and atopic diseases. The company is currently developing oral budesonide suspension (OBS) intended for the treatment of eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract.
MiReven was formed in 2010 through an investment from the Medical Research Commercialization Fund. The company is commercializing the pioneering work of Peter Leedman and Dr. Keith Giles at the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7. According to the company, miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor, as well as its associated signaling pathways that promote cancer development.
Molecular Response is an oncology-focused CRO, with a viable primary tumor bank of more than 140,000 clinical biopsies, spanning 76 diagnoses. Tumors are employed to create Patient-Derived Xenograft (PDX) models, 3D cell culture for ex-vivo pharmacology studies, and genomic surveys for target prevalence. Tumors have histology/pathology reports, ex-vivo drug resistance data and matched FFPE blocks. These platforms allow for in vivo and ex-vivo drug candidate selection, patient stratification, biomarker verification, and development of Companion Diagnostic assays in CAP/CLIA-accredited labs.
Nabsys is working on enabling advances in life sciences and healthcare through strategic deployment of a novel positional sequencing platform with broad applicability for DNA analysis. The Nabsys DNA analysis platform employs fully solid state nanodetectors that reveal both the identity and location of DNA sequences over long distances (10's to 100's of thousands of bases). The technology employs electronic detection that permits the location of sequences to be identified in a highly accurate and rapid manner. This approach allows for the identification of sequence variants of all length scales applicable to diagnostics, agriculture and whole genome sequencing.
NanoOncology is a biotechnology company that was recently purchased by PeptiMed. Its mission is to identify specific tumor-causing genetic targets and designing small interfering RNA (siRNA)-based drugs and small molecules drugs that inhibit the tumor promoting function of gene products for each patient on an individual basis. The company invented EVIRNA ™, a proprietary siRNA therapeutic drug that targets the EVI1 gene for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer. NanoOncology also invented a unique polypeptide-based nanoparticle system for delivery of siRNA directly to tumor cells.
NanoTemper Technologies GmbH develops, produces and markets innovative, high quality instruments for bio-medical research. The company, a spin off from the University of Munich (LMU), has developed Microscale Thermophoresis (MST) a new technology for biomolecular interaction measurements. The company was founded in 2008 and it has been expanding globally ever since.
NanoViricides applies nanomedicine technologies to the treatment of viral diseases. The nanoviricide® has a peptide on its surface that the company designs which mimics what's expressed on the surface of the target cell of the virus. The attachment of the surface protein of the virus to the "mimic" causes a conformational change in the nanoviricide® which then encapsulates the virus, destroying it. This has been demonstrated in over 4000 animals with 9 different viral-induced diseases.
Oligomerix is a biopharmaceutical company focused on small molecule drug discovery, immunotherapy approaches, and biomarker assay development for Alzheimer's disease (AD) and other neurodegenerative disorders. Its platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates.
Persomics has developed technology to mass-produce arrays for high content cell based screening. Their printing technology miniaturizes thousands of high content screening points onto an array, accelerating screening. Persomics mass production technology enables large scale production of high content screening arrays for the first time, providing a cost effective tool for accelerating gene and drug discovery.
PolyActiva is a biotechnology company developing drug-polymer conjugates that allow for site specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. The company has completed proof of concept studies on these and is working towards developing first products. PolyActiva is interested in medical technology companies looking to incorporate PolyActiva's drug eluting components in their devices. PolyActiva is a joint venture between CSIRO and the Bionic Ear Institute and is located in Melbourne, Australia.
Practichem is a biotechnology company specializing in chromatographic instrumentation and consumables. With a focus on both protein and small molecule purification markets, Practichem's current product line includes their Protein Purification Instrument, ARISTA and flash consumables. A performance flash chromatography instrument is also in development.
Progenitor Labs is a biotechnology company developing stem cell technologies to discover drugs that regenerate tissues of the human body. Their vision is to develop medicines that instruct organs such as the blood, muscle, bone, heart and brain to regenerate in response to injury, disease or ageing.
Prokarium is a biotechnology company with a vision to create the best platform for oral delivery of almost any recombinant protein vaccine. Its Vaxonella™ platform incorporates genetic and formulation technologies that are designed to optimize live bacterial vector-mediated antigen delivery: Spi-VEC, X-mark, ORT-VAC and BAR. Prokarium is based in Keele and London, UK.
regenHU is an innovaitve biomedical company that provides novel bio-manufacturing technologies to create new opportunities in the emerging Medtech field of Tissue Engineering (TE) by combining conventional biomedical materials with smart bioactive compounds.
Roslin Cellab is a stem cell technology company, providing stem cell contract research and product development work for academic and commercial clients in the life science, biotechnology, and pharmaceutical sectors. The company provides the opportunity to explore and exploit stem cell biology in regenerative medicine and is currently developing a number of human liver cell products which it hopes to begin making available to the drug discovery sector soon.
SAMDI Tech is a CRO that offers label-free assay services for assay development, high throughput screening, and peptide substrate discovery. The company uses its SAMDI label-free technology to perform rapid and quantitative assays of challenging biochemical targets. SAMDI is an HTS mass spectrometry tool that eliminates the need for cumbersome antibodies, fluorescence, and radioactive labels.
Second Genome is a microbiome-modulation company integrating untapped knowledge about the human bacterial ecosystem into pharmaceutical and nutritional product discovery and development.
Soluble Therapeutics commercialized the HSC™ Technology, a platform for optimizing protein formulations that can increase the solubility and stability of proteins for use as therapeutics, vaccines, diagnostics, and research reagents. The HSC Technology combines high-throughput self-interaction chromatography with a predictive algorithm to compress the amount of time it takes to derive optimal formulations for the protein in question. The HSC Technology is available on a fee-for-service basis, or companies can purchase the HSC instrument for use in their own laboratories.
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. The company's lead product, TMX-101, proved to have a good safety profile in humans during the first stage of a Phase I/II clinical trial for the localised treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Tioga Pharmaceuticals is a virtual company developing the Phase III product candidate asimadoline for the treatment of diarrhea-predominant irritable bowel syndrome.
Tunitas Therapeutics is a privately held biopharmaceutical company that is developing targeted protein therapeutics. Tunitas' proteins are capable of altering the natural course of such allergic diseases as food allergies, asthma, rhinitis and atopic dermatitis. The company's therapeutic approach offers the potential for long-lasting treatments. Tunitas is also developing a next-generation immunotherapy platform of fusion proteins which offer the prospect of long-term relief for specific allergic diseases.
Ubiquigent Limited is a specialist developer and supplier of high quality reagents, kits, and drug discovery assay development and compound profiling services to the life science research community worldwide. Ubiquigent's scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems. The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.
Venomtech is a new biotech company that focuses on venom research and supply. Their unique selection of venoms and arrays facilitate drug discovery research and help find new biological tools.
Warp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world's most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes. Key to the Warp Drive Bio approach is the company's proprietary "genomic search engine" and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature.
XL-protein is a privately owned German biotech company commercializing the PASylation technology, which allows the extension of the plasma half-life of biopharmaceuticals. XL-protein focuses on the preclinical and clinical development of PASylated proteins in several disease areas. Its goal is to provide improved second-generation biopharmaceuticals allowing less frequent and lower dosing together with better tolerability, making treatment cheaper and supporting patient compliance and safety.
- Congratulations!
You are now a GEN Select Insider!
You now have access to in-depth reports, peer reviewed papers and hot jobs.

subset: commoncrawl


text:
A parallel thread to one currently over at spawn.com I'm involved with. Just curious what you guys think of LeBron James fires agent, hires high school friends to handle financial aspects. I'd suggest it's not a particularly bright move.
If you keep LeBron's friends limited in their roles, handling his day to day finances, he probably won't get in trouble. I can see someone who is in this fantastic position wanting to help his friends. As long as he has good financial advisors giving him solid investment advice to backstop his friends, he'll probably be fine.
Page created in 0.034 seconds with 19 queries.


text:
Her Turn
"Michael has a double standard when it comes to money," says Patricia, 34, about her husband of three years. "He is a successful attorney who collects expensive wine, wears designer suits, plunks down hundreds of dollars for dinner at fancy restaurants, and takes upscale vacations. But when it comes to furniture, renovations, groceries, my wardrobe, baby gear, or gifts — in other words, stuff I value — he's a tightwad. Michael claims my spending is out of control, so now he's micromanaging our finances. He insists that I turn over receipts and flies into a rage if I've bought 'too many' bath towels or 'spent too much' on my sister's birthday present. We fight constantly. Our daughter, Allyson, is only 6 months old; I hate to think that she's growing up in a home with so much hostility.
"In fact, I'm a superb bargain hunter — I never pay retail for anything. But Michael is disdainful of the effort I spend finding the right deal. He's loving and attentive to Allyson, but he acts like I can't do anything right. Thanks to my hard work, our Philadelphia condo is beautifully decorated. But has he ever paid me a single compliment? No. All he does is criticize.
"Our approach to money reflects our different approaches to life: I'm an optimist, whereas Michael's a pessimist who is convinced a pink slip and doomsday are just around the corner. He earns a handsome salary. We're investing wisely. We pay our credit cards in full every month and carry no debt beyond our mortgage. Plus, we have plenty of discretionary income, despite the fact that I have no salary at the moment because I'm staying home with the baby. But for the past year we've fought nonstop about money. Our arguments get really ugly. Then we give each other the silent treatment for days. We're so angry we hardly ever have sex."
"I grew up in a middle-class family, the eldest of three daughters. Mom was a housewife and Dad worked in insurance. We never ate out or took vacations — luxuries I take for granted now. Still, I didn't feel deprived and overall, my childhood was happy. I'm still close with my parents and sisters.
"I met Michael five years ago at a friend's wedding. He was just out of law school and had accepted a job at a top firm in Philadelphia. I worked in sales for a fabric company. I was drawn to Michael's good looks as well as his dry wit, which shone through as we discussed movies, theater, and city life. The next day he invited me to dinner. We clicked so well that soon we were inseparable.
"Our personalities are very different: I'm spur of the moment and a bit disorganized, always juggling a million things; Michael is disciplined, efficient, and focused on the task at hand. But back then, we found our differences appealing and even joked that it would do us good if my spontaneity rubbed off on him and his responsibility rubbed off on me!"
"As newlyweds Michael and I got along great. We never argued. We ate at fancy restaurants and spent summer weekends at the beach. Things started to sour when I became pregnant with Allyson. We were surprised that I conceived immediately. In retrospect, Michael wasn't emotionally prepared for fatherhood. As my pregnancy progressed, he became increasingly stressed out about the financial responsibility of raising a child.
"Since our one-bedroom condo was too small for a family, we bought a two-bedroom in a luxury high-rise. We got a great deal, but the place needed a total overhaul. I missed a lot of work in my first trimester because of horrible morning sickness, so I quit my job and focused on the renovation, hiring and supervising the architect and a platoon of contractors. We created a budget, but we grossly underestimated the costs and how long the project would take. As it stretched on, Michael became more and more nervous about the escalating expense. When I asked him to help make decisions, he dragged his feet until I ended up deciding alone — only to face his criticism after he saw the bills.
"One of our most vicious fights was about $2,500 I spent on a still-life painting for our foyer. The artist is a friend and he gave it to me as a 'loaner' so we could see whether it was right for our space. I adored it, and my friend offered to sell it to me for half price. Michael lost his temper when he saw the canceled check. He claimed I bought the painting 'behind his back,' yet I distinctly recall that he never gave me a straight answer when I asked whether he liked it."
"We also argue about what I spend on baby stuff. At an upscale store, I fell in love with a $1,100 crib that converts to a toddler bed, but I did my homework and got it for $800 at an online outfit. Yes, it was expensive even with the discount. Yes, I could buy a crib at Sears for a lot less money. But it's a beautiful piece that will be in our family for generations, and we could afford it. Still, Michael went ballistic when the bill came in. That's when he demanded that I hand over every receipt for his review.
"The renovation project is almost over, but not our fights. Michael thinks I buy too many clothes and shoes for myself and just the other day screamed at me for 'hiding' my purchases in the back of our closet and accused me of lying. It's true I don't go out of my way to tell him what I've bought. But does that make me a liar? What about his spending? I haven't noticed him cutting back on his wine collection.
"Recently, Michael has been staying out late at client dinners, drinking too much and forgetting to tell me he'll be late. I know he's doing this to spite me. In addition to his work and money worries, Michael is angry that I don't pay as much attention to him as I used to. But how can I? After a long day with the baby and everything related to the renovation, I'm wiped out. I still love Michael and don't want a divorce, but I can't bear the way things are now."
His Turn
"So Patricia thinks I'm a tightwad," said Michael, 30, in a clipped tone. "Well, I call it being financially responsible. We're investing for our retirement and our daughter's education, but I'd like us to stash away more of my salary. My wife just wants to spend it.
"Patricia goes overboard on everything. She buys too much food — and she shops at gourmet stores, not supermarkets. She's extravagant when it comes to clothes for herself and Allyson as well as gifts for friends and family. She owns 75 pairs of shoes; her side of our closet is so packed I don't know how she finds anything. Yes, I flew off the handle after she spent $800 on a crib. And yes, I now insist she turn over all her receipts. I got tired of being unpleasantly surprised every month when the bills rolled in. But I'm hardly the cheapskate she makes me out to be: I collect fine wine and pay top dollar for business suits. Like Patricia, I like having a nicely furnished home. But do we need a designer sofa? Won't a moderately priced one do?
"Sometimes I think I'm just a paycheck to Patricia. When I ask her about bills, she ignores me or gets defensive. So then I yell or make hurtful comments, thinking maybe that will get through to her. It doesn't. Patricia hasn't reduced her spending. Our relationship is in shambles. Our sex life is all but nonexistent.
"My cautious attitude about money is rooted in my childhood. Mom was a housewife who doted on her four kids. Dad was a lawyer who squandered his salary on alcohol. My parents ended up getting divorced when I was 18, and at retirement my father had nothing but Social Security to live on. I do not want to end up like him. I worked part-time at a supermarket in high school to earn money for college because Dad wouldn't pay for it. I put myself through law school with loans I'm still paying off. I find it ironic that I'm now the one accused of being 'cheap.'"
"Patricia is the most beautiful, energetic woman I've ever met — the kind of person whose natural radiance attracts people. On the night we met she was a font of information on Philadelphia, where I was a newcomer. Within a few months, I was madly in love. Patricia brought an excitement to my life that I hadn't known I was missing.
"When we were dating I sensed that Patricia was more liberal with money than I was but I didn't realize how wide the gap was until we started remodeling the condo. We set a budget for everything, and I made it clear that I wanted to stick to it. With a baby on the way, I felt anxious about the expense of raising a child. I wanted to exercise some restraint, especially since Patricia stopped working after her first trimester. I didn't mind that — she was so sick in the beginning she could barely work anyway — but I don't like the fact that she disregarded all my concerns. If she found something for our home that was beyond our budget but that she couldn't resist — the antique light fixture in our bathroom, for instance — she'd buy it without telling me. Or she'd upgrade to more expensive sinks and faucets, saying the investment would enhance our resale value. I wouldn't know about these purchases until I looked in the checkbook. One of our worst fights was over that painting. I've hated it since the day her friend loaned it to us and I've repeatedly told her so. But Patricia has a selective memory. As for her claim that I don't help her make decisions, well, what's the point? She'll do what she wants anyway.
"Patricia is deceitful in other ways, too. It's gotten to the point where she hides her purchases in places she thinks I won't look. Once I came across an expensive leather handbag with the tags still on it wedged behind pots and pans in a kitchen cabinet. When I asked her about it, she cried and accused me of not loving her.
"Yes, I'm guilty of staying out late with clients and not calling. Yes, I'm guilty of drinking a bit too much these days. I'm ashamed of this behavior, but I'm so unhappy at home that client events have become a refuge. I love my wife, and I want our marriage to work, but this money situation cannot continue."
The Counselor's Turn
"Both Michael and Patricia found in the other what they were looking for in a mate — a complement," said the counselor. "The spontaneous, but scattered, Patricia needed a man who was practical and organized, while the reserved, but controlling, Michael needed a woman who was more exuberant. Yet, as often happens, the very qualities that drew them together now threatened to tear them apart.
"Why is this? If you marry your complement, it's vital that you accept your differences. If you try to change the other person, you'll butt heads for the rest of your lives. That's what was happening here: Patricia's spontaneity contributed to her impulsive spending, and she was furious when her husband assumed a paternalistic role. His controlling nature contributed to his fiscal caution, and he was furious that she was irresponsible with their money.
"The arrival of a baby usually amplifies such differences. That was the case with Patricia and Michael, who didn't expect to become parents so quickly. He was still reeling from the reality of impending fatherhood when Patricia's spending on everything began to escalate. Michael retaliated by distancing himself from Patricia and becoming tighter with money. When the couple started counseling, they were so angry they didn't even listen to each other."
"My first task was to get them to understand how their families had shaped their attitudes about money. As a child, Patricia never imagined that she'd have access to the type of money that Michael earns, and she was behaving like the proverbial kid in a candy store. Her inherently disorganized nature contributed to her impulsiveness. For example, if she found towels on sale, she'd buy four sets, even if she needed only two. Excessive spending can be a cry for help. But I think for Patricia the inclination was a function of her background and sincere desire to create a beautiful home. The fact that she took so much pleasure from decorating reinforced her extravagance.
"For Michael, a fear of ending up like his father turned him into a fiscal conservative. Although he was generous early in the marriage, the more he offered Patricia, the more she wanted. By pushing the limits, Patricia was turning her husband into a controlling daddy figure.
"I helped Michael see that Patricia's spending was not driving them into debt, and I helped Patricia see that Michael's concerns about his job security and his desire to save money were reasonable. They needed to strike a balance between their extremes. For Patricia, that meant creating budgets for renovation projects, general household expenses, and clothing and sticking to them. She also had to stop spending impulsively, to stop rationalizing that she bought only 'on sale,' and to stop hiding purchases or lying about them to Michael.
"Meanwhile, I urged Michael to stop questioning and reviewing Patricia's every purchase, and to stop being scornful of the time she devoted to the renovation. To allay some of his anxiety, the couple decided to earmark more of his paycheck for investments, making less discretionary income available. They started doing so once the renovation was complete."
"Additionally, the couple had to learn to communicate more effectively. Their pattern of not listening, interrupting, screaming, and name-calling only created more and more ill will. 'It's okay to be upset and say, Why did you do that?' I explained, 'but it's not okay to debase one another.' Meanwhile, with no prompting from me, Michael stopped staying out late and drinking too much. He also came to see that it was both unrealistic and selfish to expect Patricia to lavish the same amount of attention on him that she had given before they became parents.
"I also encouraged Patricia and Michael to be more accepting of each other's personalities. Although people can modify their behavior, they cannot change their core beings. This is a big issue in couples counseling, because spouses often want to change the other spouse in ways that are impossible. It's not as if Patricia will never overspend again or that Michael will become a spendthrift. These two will never see eye to eye on everything — and that's okay. What's most important is that they reach an acceptable compromise.
"Finally, I encouraged Patricia to consider turning her passion for decorating into a profession. Michael, who came to appreciate his wife's skills, agreed and encouraged her to get accredited as an interior designer. Patricia has done this and is planning to launch her own business when Allyson starts preschool.
"The couple spent two years in counseling, working hard to make the changes that ultimately saved their relationship. Not only do they now set and largely stick to a budget, but they also save a larger percentage of Michael's salary. They've also learned to listen more respectfully to each other's concerns. As their relationship improved, they felt more loving toward each other, and their sex life improved. 'Counseling helped me understand myself better,' Michael told me recently. 'I'm not as uptight about money as I used to be. I realized that Patricia didn't spend money to be vindictive. Rather, she did it to maintain a lifestyle that was within our means.' Both Patricia and Michael credit counseling with making them more patient with each other. 'Best of all,' adds Michael, 'we've fallen in love all over again.'"
"Can This Marriage Be Saved?" is the most enduring women's magazine feature in the world. This month's case is based on interviews with clients and information from the files of Mindy R. Schiffman, PhD, a clinical psychologist and certified sex therapist in New York City. The story told here is true, although names and other details have been changed to conceal identities. "Can This Marriage Be Saved?" is a registered trademark of Meredith Corporation.
Originally published in Ladies' Home Journal magazine, March 2006.


text:
OM PIPES & FITTINGS INDUSTRIES is a manufacturer and supplier of T Pipe . T Pipe is one of our top exported products around the world. Our company is ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007 & PED 97/23/EC Certified. T Pipe can sustain high pressure and temperature rating. T Pipe are majorly used in hydraulics, pneumatics, oil and gas industry, petrochemical industries, energy projects etc. Our company specializes in fast delivery at best prices. We are the top company in India for manufacture and supply of steel products. Our products have been exported internationally to more than 80 countries. We have clientele all around Europe. We provide MTC in accordance with EN10204 NACE 3.1. Send us your inquiry for T Pipe on firstname.lastname@example.com
Product features
|Seamless Pipe Fitings,Welded Pipe Fittings,ERW Pipe Fittings,Fabricated Fittings
|1/2″ to 48″
|Schedule 5,10,10S,40,40S,STD,80,80S,XS,120,160,XXS
|Plain End,Bevelled Ends
|Butt weld Fittings – ASME/ANSI B16.9 ; Socket Weld Fittings – ASME/ANSI B16.11
|Butt weld fittings -ASTM A403 ,Socket weld Fittings Pipes-A182
|Hs Code
|Butt weld fittings-73072300 ,Socket weld Fittings-73072900
- Stainless Steel FlangesBlind Flange Slip On Flange Weld Neck Flange VIEW THE PRODUCT PAGE
- Stainless Steel TubesStainless Steel Tubing SS Tubes Straight & Coiled VIEW THE PRODUCT PAGE
- Stainless Steel Pipes SS Pipes Seamless Pipes & Welded Pipes ( ERW , EFW ) VIEW THE PRODUCT PAGE
- Stainless Steel SheetsJindal Make - Indian Origin VIEW THE PRODUCT PAGE


text:
HAVANA (AP) — Cuban state media have announced 11 deaths from Hurricane Sandy, including a 4-month-old boy who was crushed when his home collapsed.
State TV's nightly newscast says nine of the deaths were in Santiago province in eastern Cuba, which is home to Cuba's second largest city. It is also known as Santiago.
The other two deaths were reported in Cuba's Guantanamo province, bordering the U.S. naval base at Guantanamo Bay.
The newscast says the oldest victim was an 84-year-old man in Santiago province.
The report of the deaths came at the end of the newscast.
Cuban authorities say most of the fatalities occurred when dwellings fell down, but the cause of others is still being investigated.


text:
Art of Fighting (PlayStation 3)
Published by
Developed by
Also For
Critic Score
100 point score based on reviews from various critics.
User Score
5 point score based on user ratings.
DescriptionYuri Sakazaki has been kidnapped! Her big brother Ryo Sakazaki and Robert Garcia, his best friend, go search for her on the streets of South Town. As they go deeper and deeper they will find clues as to who ordered the kidnapping, the Sakazaki family's relation to the mob, and a person from their past.
The gameplay differs from most fighting games. In this game, you have a Spirit meter. A Spirit meter is in the game and will decrease as you perform special moves. It can be recharged, but doing so leaves you open to attack. When your health is almost gone, you can perform a secret combination that will unleash a deadly attack on your opponent - provided you have a full Spirit meter.
The arcade version doesn't allow you to play as Mr. Big and the elusive Mr. Karate.
There are no PlayStation 3 user screenshots for this game.
There are 137 other screenshots from other versions of this game or official promotional screenshots.
Promo Images
Alternate Titles
- "龍虎の拳" -- Japanese spelling
- "Ryūko no Ken" -- Japanese title
- "용호의 권" -- Korean spelling
Part of the Following Groups
User Reviews
There are no reviews for the PlayStation 3 release of this game. You can use the links below to write your own review or read reviews for the other platforms of this game.
Critic Reviews
There are no critic reviews for this game.
There are currently no topics for this game.
ContinuityAccording to SNK's original timeline, the events that happen in this game take place ten years before Fatal Fury; however, when the The King of Fighters series was created, both timelines were merged, even though the backstories for both series remained mostly the same.
InnovationsNot only did Art of Fighting have the honor of being the first fighting that introduced the 'camera zoom' - where the camera zooms in whenever the fighters are close together, and zooms out when the fighters move away from each other - but it also was the first to utilize a 'spirit meter'. Every time a fighter executes a special move, the spirit meter is depleted accordingly, and the more powerful the special move, the more it depletes. When this meter is empty, special moves can no longer be executed.
Title translationThe Japanese title, Ryūko no Ken, translates to "Dragon and Tiger Fist".
Informatiion also contributed by B14ck W01f
Related Web Sites
- IGCD Internet Game Cars Database (Game page on IGCD, a database that tries to archive vehicles found in video games.)
There are no game credits on file for this release of the game. Everything in MobyGames is contributable by users.


text:
EDISON — An open house for prospective Middlesex County College students and their families will be held Sunday, Nov. 6 from 11 a.m. to 1 p.m. in the College Center on the Edison campus.
High school students who are considering continuing their education at Middlesex, as well as anyone who is thinking about taking a course at the College, are invited to attend. Refreshments will be served. To register online, visit www.mccopenhouse.com.
In many programs, students earn an associate's degree and then transfer into a four-year college or university as members of the junior class. Working closely with their faculty and advisors assures this seamless transition and they find that the cost of their undergraduate education is substantially lower because of their work at Middlesex.
The college offers formal credit articulation transfer agreements and/or dual-degree admissions programs with more than 50 four-year institutions, including Rutgers, Montclair State, Kean, and NYU. It has always been the largest "feeder" school to the New Jersey Institute of Technology (NJIT) where its graduates are continually recognized for their outstanding academic achievements.
In other academic programs, the students graduate from Middlesex and go right into a career.
"There is no better value in higher education today than the community college," said College President Joann La Perla-Morales. "Our tuition is about one-third of what the public colleges and universities charge and a fraction of the cost of the private schools. In addition, many scholarships are available through the Middlesex County College Foundation."
At the open house, professors, advisors and administrators will conduct workshops and information sessions addressing everything a student needs to know about attending and being successful at Middlesex.
Aretha Watson, director of admissions and assistant dean of enrollment and student support services, said the open house will allow prospective students to get a taste of what Middlesex has to offer.
"The Open House will provide the opportunity to learn about all the College's offerings, including the many dual admissions programs with four-year colleges and universities, career opportunities, financial aid and career services," she said.
Adult students can learn about the CARE program, which assists adults who attended college within the past decade but did not graduate. There will be representatives from all academic areas, including the college's Honors program who will talk about opportunities for high-achieving students. Services for military veterans will be explained. College ambassadors will conduct campus tours and discuss student concerns.
For more information, visit www.middlesexcc.edu.
Connect with NJTODAY.NET
Join NJTODAY.NET's free Email List to receive occasional updates delivered right to your email address!


text:
In honor of St. Patrick's Day, we are posting one of our favorite and most creative customizations of our Larkspur design. Inspired by the Larkspur invitation and building on the fact that any of our suites can be customized, Antoinette at PAPERISTA helped Katy and Colin design the perfect save the date for their upcoming wedding.
The change in the color palette to leaf and garden green immediately speaks to the couple's Irish heritage, but the fine details are what make this save the date truly personal. The pattern on the first panel of this trifold save the date was updated with a Celtic knot in place of the olive green button detail in the original. Perfectly placed motifs like the shamrock on the first and second panels as well as the satin gold foil claddagh on the second panel and the row of Celtic knots on the last panel make this piece sweetly unique. Antoinette, Katy and Colin really took the ability to customize to the next level! Take a peek at the gorgeous results!
Aren't their customizations just the perfect touch?! We're working on their invitation suite right now too — it's right in line with this classically beautiful and personal piece. We will be sure to share it with you once they're printed and mailed!


text:
|International Space Station Imagery
high res (0.5 M) low res (37 K)
|ISS007-E-14745 (13 September 2003) --- This close-up view of the eye of Hurricane Isabel was taken by one of the Expedition 7 crewmembers onboard the International Space Station (ISS). At the time this photo was taken, Isabel had reformed to a Category 5 storm, packing winds of 160 miles per hour.
Curator: JSC PAO Web Team | Responsible NASA Official: Amiko Kauderer | Updated: 10/30/2012


text:
House approves spending bill that boosts funding for Virginia-class submarines
The U.S. House of Representatives approved a spending bill Wednesday that provides 22 percent more funding for the Virginia-class submarine program, while many other defense programs will be cut or increase modestly.
"Despite the fact that overall spending for defense is going down and we're not able to fully restore the cuts under sequestration, the Virginia class is listed as one of the items that got a plus-up," U.S. Rep. Joe Courtney,
D-2nd District, said. "Almost no other place in the entire budget — domestic or military or within the Pentagon — got that kind of a profound vote of confidence."
In the $1 trillion omnibus appropriations bill for fiscal 2014, $6.5 billion was allocated to build two submarines a year in 2014 and in 2015 and to restore funding that was cut due to the automatic sequestration reductions, which is $1.2 billion more for the program than the president's budget requested.
This agreement fully funds the second submarine for 2014 this year, where in the original plan the bill would have been paid in 2014 and in 2015.
The appropriations bill also provides $1.1 billion to continue the research and development on a new class of ballistic-missile submarines to replace the Ohio class, and $59 million so Electric Boat can continue developing a module that will boost firepower on Virginia-class submarines.
If the government had continued to operate under a continuing resolution, which freezes spending at last year's levels, the Navy would have received about half as much for the work on the Ohio-class replacement. EB is designing the submarine.
Construction on the lead ship is scheduled to begin in 2021, but that likely would have been delayed if the research and development slowed this year, Courtney said.
EB President Jeffrey S. Geiger said Tuesday, after the plan was first announced, that it was "the very best news we could've hoped for."
The Senate is expected to pass its appropriations bill later this week. U.S. Sen. Richard Blumenthal, D-Conn., said the bill includes "critically important funding for national security priorities and provides significant certainty for the manufacturers, big and small, in Connecticut's defense industry supply chain."
Courtney said he is thrilled that the submarine programs will stay on track and the work that is being done in southeastern Connecticut will be supported.
"It's sensational," he said. "It speaks so powerfully to the commitment the country is making to its undersea fleet."


text:
2018 Bempton Cliffs Photography Workshops
- Bempton Cliffs, East Yorkshire
- from £195.00 (see pricing table below)
Bempton Cliffs is home to over 400,000 seabirds from March to September. This is a very exciting place for wildlife photography, with many great opportunities to capture all the species close up, from the birds on the cliff-face to those in flight.
Key Species: - Puffin, Gannet, Kittiwake, Fulmar, Guillemot, Razorbill, Herring Gull and Shag.
This 1 to 1 or 2 to 1 photography workshop will be tailored towards beginners, enthusiasts and photographers who want to learn more about the different aspects of wildlife photography. We will start with a look at the techniques and equipment needed with advice and tips on how to capture that perfect wildlife image.
You will learn about correct exposure, how to deal with tricky lighting conditions such as harsh sunlight or low light levels, depth of field techniques, apertures, ISO, autofocus, shutter speeds and composition. Advice will be given regarding the different species of seabirds and the incredible seabird colony in which they raise their young.
Facilities: The newly built Seabird Centre includes an interpretation area, shop, toilets, picnic area and five cliff-top viewpoints.
Please note: If you would like to attend on a particular date listed below, but would prefer a different type of workshop, e.g. half day, group session etc, please contact the YCN office on 01723 865498 and we may be able to accommodate you.
Steve Race is our lead photographer at Yorkshire Coast Nature. From his start with a film camera in the early eighties right up to the digital era of today, Steve has acquired a great eye for wildlife photography. His passion for the natural world shines through on his workshops and tours with YCN. In 2013... Read More


text:
Driver fleeing police crashes in KC
At least 1 person suffers serious injuries
Driver fleeing police crashes in KC
At least 1 person suffers serious injuries
KANSAS CITY, Mo. —
Kansas City police said at least one person was injured after a chase ended in a crash.
Police said they attempted to pull over the driver of a red Chevolet Camaro near Ewing Avenue and Truman Road, but the car sped away from the scene. It crashed into an SUV near the intersection of Independence and Bennington avenues.
"It was traveling at a high rate of speed through residential areas, so we're lucky that a child wasn't injured," said Sgt. Deetta Jacobs of the Kansas City Police Department.
Investigators said the driver of the Camaro was seriously injured. His name has not been released.
Police said the Camaro may have been stolen.


text:
Sentence Completion Practice Test 2
Question 1
Although is seems to have been a fixture of the square since the city's origin, the produce market actually opened only _______.
- enthusiastically
- recently
- frequently
- illegally
- graciously
Correct Answer: B
The use of the conjunction 'although' indicates a contradiction within the sentence. If the market seems to have been in existence since the city began, it must have been opened a long time ago. But the use of the conjunction 'although' implies that this is not so. So, it must have been opened only recently. So, (B) is the answer.
Question 2
The grave problems that afficted him were the purely _______ ones of hunger, pain and fatigue.
- physical
- imaginary
- irrelevant
- hereditary
- coincidental
Correct Answer: A
Hunger, pain and fatigue cannot be described as imaginary, or irrelevant, or hereditary, or coincidental problems. They can best be described as physical problems. So, (A) is the answer.
Question 3
Her ability to analyze issues fairly and competently has earned her the _______ of even her most _______ peers.
- solicitation.. unbiased
- attention.. sympathetic
- suspicion.. discerning
- reputation.. knowledgeable
- respect.. exacting
Correct Answer: E
An ability to analyze issue and competently will not result in solicitation (meaning begging) or suspicion. So, (A) and (C) can first be ruled out. The use of the phrase 'even her' in the second part of the sentence rules out the adjectives sympathetic and knowledgeable in (B) and (D). It is the pair of words in (E) which completes a meaningful sentence, and is the answer.
Question 4
Until the mid- 1800's, the occasional reports by European explorers of the existence of gorillas were generally disbelieved and swiftly _______ the realm of tall tales.
- extracted from
- confused with
- relegated to
- compared to
- exalted to
Correct Answer: C
Stories that are generally disbelieved would be pushed into the category of tall tales (meaning lies), Among the choices, it is phrase 'relegated to' that has this meaning. So, (C) is the answer.
Question 5
The historian's assertion that there is a _______ of verifiable information about nineteenth-century Native Americans is _______, for there exist many transcripts of authentic oral accounts of their activities.
- wealth.. fallacious
- shortage.. legitimate
- depletion.. irrefutable
- paucity.. erroneous
- surfeit.. implausible
Correct Answer: D
The second part of the sentence says that there exist many transcripts of genuine accounts of the activities of Native Americans. So, the first part must mean either that the historian 'correctly asserted that there is a lot of verifiable information', or that he wrongly asserted that there is little of verifiable information'. Among the choices, it is (D) which means the latter, and is the answer.
Question 6
This book has neither merit nor distinction, and it all but _______ whatever prestige the author may once have had.
- challenges
- maximizes
- epitomizes
- nullifies
- encompasses
Correct Answer: D
: If the author of the book had prestige earlier, but has now produced a book which has neither merit nor distinction, the new book would nullify his earlier prestige. So, (D) is the answer.
Question 7
Far from exercising a counter influence to intellectual orthodoxy, the movement itself has become a center of _______.
- conformity
- notoriety
- enmity
- theology
- idealism
Correct Answer: A
The use of the phrase 'far from becoming a challenge to intellectual orthodoxy' implies that the new movement has also become something similar to such orthodoxy. Among the choices, it is the word 'conformity' which is closest to the word 'orthodoxy'. So, (A) is the answer.
Question 8
People, being prisoners of _______, have made failing a basic metaphor for failure, from the fall of the stock market to the fall of government.
- politics
- gravity
- greed
- turbulence
- emotion
Correct Answer: B
The author says that the use of the word "fall", as a metaphor to represent "failure", arises out of the people being prisoners of something. Among the given choices, it is gravity that is the best choice, because it is gravity that brings wn every physical object from a higher (success) to a lower (failure) level. So, (B) is the answer.
Question 9
The movie avoids many of the _______ of the novel, bringing into sharper focus characters who originally were amiable or disagreeable _______.
- subtleties.. monsters
- excellencies.. stereotypes
- allusions.. individuals
- particulars.. nonentities
- shortcomings.. blur
Correct Answer: E
If the movie had brought the characters in the novel to a sharper focus, those characters must have been portrayed with less sharpness in the novel. Among the choices, it, is 'stereotypes; and blurs' which have this meaning. But 'stereotypes' cannot be described as excellence of a novel. So, (B) can also be ruled out. The pair of words in (E) completes a meaningful sentence, and is the answer.
Question 10
Even the most insulated and _______ government has to be concerned today about the popular mind; some systems may be less _______ than others, but at some point all must pay attention.
- parochial.. vociferous
- corrupt.. theoretical
- arbitrary.. sensitive
- obscure.. reined
- vibrant.. responsive
Correct Answer: C
The last phrase in the sentence, "but at some point, all most pay attention" implies that the second missing word must mean 'attentive'. Among the choices for this word, it is only 'sensitive' and 'responsive' which have this meaning. But an insulated (meaning with no touch with the people) government cannot be described as a vibrant one. So, (C) is the answer.
Question 11
Explanations given to the patient by the anesthetist prior to surgery often _______ anxiety and _______ the need for analgesics.
- intensify.. counteract
- parallel.. assume
- explore.. prepare
- relieve.. reduce
- ignore.. preclude
Correct Answer: D
If an anesthetist (the physician who administers chloroform) gives some explanations to the patient before the surgery, it will not be with a view to intensify his anxiety, but to relieve his anxiety. If this is so, there will be less need to give him analgesics (meaning 'drugs which produce insensitivity to pain'). So, (D) is the answer.
Question 12
The jellyfish's show pulsing action people it in a graceful, seemingly _______ drift, but its tentacles contain poison potent enough to stun a swimming human.
- sinister
- rhythmic
- murky
- harmless
- patient
Correct Answer: D
The use of the conjunction 'but' implies a contradiction within the sentence. The second part says that the jellyfish's tentacles contain a poison which can kill a swimming human. So, to justify the use of the conjunction 'but', the first part must imply that the jellyfish looks 'harmless'. So, (D) is the answer.
Question 13
The production's slight romantic appeal depends on its two stars, who are _______ to watch oven when they are delivering _______ speeches.
- overbearing.. innocent
- farcical.. complex
- attractive.. creative
- impossible.. dull
- pleasant.. empty
Correct Answer: E
The use of the conjunction 'even when' implies a contrast within the sentence. So, the two missing words must mean the opposites of each other. If the drama's appeal depends on its two stars, it means that they are either 'attractive' to watch or 'pleasant' to watch. But the pair of words in (C) does not justify the use of the phrase 'even when'. So, (E) is the answer.
Question 14
The murderous capriciousness of Nero infused the Roman Empire with such pervasive _______ that not even the most _______ citizens felt safe.
- distaste.. vulgar
- paranoia.. suspicious
- enthusiasm.. apathetic
- unease.. oppressed
- panic.. distinguished
Correct Answer: E
Her again, the phrase 'not even' implies a contrast within the sentence. Among the choices for the second missing word, it is only 'distinguished' that will bring out this contrast. Its pair word 'panic', meaning 'great fear', could well have been the result of Nero's murderous capriciousness. So, (E) is the answer.
Question 15
His inclination to succumb to flattery made him _______ to the _______ of people who wished to take advantage of him.
- immune.. predilection
- prejudicial.. intentions
- susceptible.. cajolery
- resistant.. blandishments
- amenable.. rejection
Correct Answer: C
If a person was inclined to succumb to flattery, people who wished to take advantage of him would naturally flatter him. Among the choices for the second missing word, it is only 'cajolery' and 'blandishments' which mean 'flattery'. But the pair word of 'blandishments', namely 'resistant', would result in a self-contradictory sentence. So, (C) is the answer.


text:
You are here: Home ‹ Board index ‹ Movie Discussion ‹ Upcoming Movies
Fire Marshall Bill Movie?
Discuss other upcoming Jim Carrey movies (not confirmed/rumours).
11 posts • Page 1 of 1
Fire Marshall Bill Movie?
I saw this on IMDb on the discussion board and wondered what yall would think.
To God, every living being is beautiful... Except for you.
Good idea, unless Jim can still do that 'face-holding' thing however I'm sure a makeup artist can help support it!
"Snakes! Why it had to be snakes?"
-Raiders of the Lost Ark (1981)
It'd be like SNL stars making movies out of their characters. (Wayne's World, A Night at the Roxbury)
To God, every living being is beautiful... Except for you.
I think it would be funny but I don't think Jim would do it. The same thing as Ace I guessing. You never know what the future may hold though!
Nah, I think that era has passed. They could make a Stewart - Mad TV- movie, that'd be awesome if the guy is up to it.
"Lemme do it!"
Though the Fire Marshall would be awesome and funny, we're in a new age with computhiingys and gigity gadgets and things that flash in the night, and i don't think many of my pubescent age would be interested-and we all know what happens when teens aren't into things. . . .
"No time outs. Only DEATH!"
"I don't like to brag and I won't cuz I don't have to!"
11 posts • Page 1 of 1
Who is online
Users browsing this forum: No registered users and 3 guests


text:
"A lot of films have been made around poverty, a lot of guilt-based films, and we thought we could tell this story in a new way that was really tailored to the millennial generation."
We spoke with filmmakers Chris Temple and Zach Ingrasci about their 8-week experiment in rural Guatemala living on $1 per day, the typical income for this extremely impoverished region. Their inspirational documentary, Living on One Dollar, follows their encounters with hunger, parasites, and the generous local community as they strive to understand first-hand what life is like below the poverty line.
On first entering the Guatemalan community:
"We were four Americans coming into a village where we didn't have any connections, trying to figure out how to survive, and the kids would come up and just stare at us, watching for hours. It was the kids who really bridged the gap between us and the rest of the community."
On their living arrangements:
"We lived in a small mud hut and slept right on a small pad on the dirt floor, with two blankets between the four of us. The worst part was that the dirt floor had fleas, and you can see in the film where we're just covered in red bites. There was one morning where I [Chris] woke up with both giardia [a parasite] and E. coli, and we didn't know if we had enough money to budget for food, let alone the cost of medicine."
On farming to help make ends meet:
"We wanted to simulate starting a business in this community, so we took out our own microfinance loan and worked during the day as radish farmers. Trying to do 8 hours of manual labor when we'd only eaten one small bowl of rice and beans, which was all that we could afford, and when we hadn't had a good night's sleep, was just debilitating, both physically and mentally."
On the value of microfinance loans:
"One of the most powerful stories we heard was from Rosa, who is featured in the film. In sixth grade, she had to drop out of school to help feed her family, but she always dreamed of becoming a nurse. As an adult, she took out a $200 microfinance loan to start her own weaving business and was able to send herself back to school with the profits. A $200 loan provided this opportunity for her to empower herself and bring herself closer to her dream."
On what they hope viewers will take away from their documentary:
"What we hope people walk away with is to believe that small efforts can really make a big impact on the life of someone living in extreme poverty, and to believe that we can all make a difference."
Living on One Dollar will be available exclusively in the U.S. through Hulu and Hulu Plus from April 22-May 3 to coincide with "Live Below the Line", an anti-poverty awareness campaign encouraging people around the world to try living for five days on $1.50 per day for food and water.
Visitors to Chris and Zach's nonprofit site livingonone.org can get involved by learning about or donating directly to microfinance organizations that provide loans in impoverished areas. Schools, churches, and other community groups worldwide can also book a personalized Living on One Dollar screening with the filmmakers to discuss what we can all do to make a difference.


text:
Four Somali journalists have been killed in the last two days in Mogadishu, the capital of Somalia, in what appears to be a campaign of assassination by unknown assailants.
Three were killed Thursday evening when two men blew themselves up at a popular hangout for journalists and political activists known as The Village. Six other journalists were wounded in the attack. Fourteen people in all died in the blast.
On Friday, a radio journalist was gunned down at a Mogadishu intersection.
The killings bring to 10 the number of local journalists who've died this year in what Tom Rhodes of the Committee to Protect Journalists called "the deadliest year for Somali journalists since this conflict began" more than 20 years ago.
Rhodes singled out militia groups and members of the previous Somali government as possible suspects in the attacks.
The U.S. Embassy in Nairobi, where U.S. diplomatic efforts toward Somalia are based, said in statement that the attack "on a cafe known to be frequented by students, scholars, journalists and politicians underscores the attackers' contempt for Somali lives and culture."
The location was known as a popular journalist hangout. A McClatchy correspondent was among about 10 journalists who'd gathered there Thursday afternoon but had left the restaurant about 20 minutes before the attack. He returned to find friends dead and others wounded at the bloody scene.
Somali journalists and Rhodes said they believe journalists were the primary targets of the Thursday bombing.
On Friday, Hassan Yusuf Absuge, a director at the privately owned Radio Maanta, was assaulted by men carrying pistols at a busy Mogadishu intersection. The men shot him in the head and he died immediately, according to news reports.
While most violence in Somalia has been blamed for years on al Shabab, the Somali affiliate of al Qaida, few here see them as likely suspects, given that Shabab's forces were pushed out of Mogadishu last year. More likely suspects, many say, are to be found among Somali politicians who know such acts routinely will be blamed on Shabab.
The uptick in violence against journalists comes even as the Somali capital has grown more stable. The Village, where the Thursday attack occurred, was recently opened by one of many Somali businessman from the diaspora who are returning to invest in the city's reconstruction.
Pictures of the three journalists killed Thursday, posted online, highlight another sad reality: They were all young men. Rhodes said that's because older journalists have been killed, fled or decided journalism was not worth the risk.
The National Union of Somali Journalists has said that the lack of any arrests or reprisals for the attacks is only emboldening whoever is behind them.
"The culture of impunity has become ever more strongly entrenched because of the failure to bring those responsible for the murder and harassment of journalists to book," the group's secretary general, Omar Faruk Osman, said in a statement posted to the group's website on Friday.


text:
Eddie Watson Britt, 66, of Lexington, passed away at his home on Saturday, July 27, 2013, with family by his side.
A celebration of Eddie's life will be at 3 p.m. Wednesday at Davidson Funeral Home, Hickory Tree Chapel by Pastor Allan Paschal.
Visitation will be one hour prior to the service.
Eddie was born on May 20, 1947, in Rosinville, S.C., to Johnnie Franklin Britt and Grady Wagers Britt. He was retired from HFCS and was of the Methodist faith.
He was preceded in death by his parents; brother's Ellison Britt, Homer Wolfe and Terrel Wolfe; and sister Maxine Wolfe.
Surviving are his wife of 44 years, Karen Belt Britt, of the home; sons Jeff Britt and wife Tammi of Lexington and Jason Britt of Walnut Cove; grandchildren Justin Britt, Jade Britt, Hunter Britt and Madison Britt; brothers Roy Britt, Teddy Britt, Danny Wagers, LB Wolfe, Frankie Britt, Tony Britt and Kent Britt; sisters Susie Wannamaker, Sadie Weathers and Reba Dell Ahl, all of South Carolina.
In lieu of flowers send donations to Hospice of Davidson County, 200 Hospice Way, Lexington, NC 27292.
Online condolences may be made at www.davidsonfuneralhome.net.
Eddie Britt
Eddie Watson Britt, 66, of Lexington, passed away at his home on Saturday, July 27, 2013, with family by his side.


text:
|2004-04-11, 13:35
|Link #3
Evangelist of the Kazoo
Join Date: Apr 2003
Location: AnimeSuki Forums
Yes, Happy Easter indeed! Let's all worship the pagan god of fertility Fria and scavenge around for the symbols of fertility, the rabbit and egg. While we're at it, let us also pray for a good mating ritual tonight.
|2004-04-11, 13:59
|Link #6
in silent opposition
Can I put my college kid without a family rant here? Oh well, atleast it's not as depressing as eating a bag of chips for thanksgiving dinner. And who knows!! Maybe I'll make tonight special and order out a pizza! Who needs eggs and ham to have a good easter anyway!? Not me thats for sure!! ;_;
|2004-04-11, 14:04
|Link #7
Join Date: Jul 2003
Location: Austin, TX
Age: 36
Heck yeah! I'm in the same boat Tzurial. I was thinking about going to go to a $6.25 all-you-can-eat Chinese buffet tonight. I'm spending today grading a stack of over 100 papers, doing homework, writing an essay, e-mailing professors at my future grad school, and applying for some internship jobs. I've got a to do list with 12 items, each which will take me at least one hour to complete. Looks like I'm not sleeping tonight...
|2004-04-11, 14:15
|Link #8
the Iniquitous
a little informative list of what we do here in Colombia
This whole week is the hollyweek "semana santa", that means vacations for everyone!! in shchools is usually the whole week, but oficcially only from thursday to sunday is a rest day.
The sunday ( not this but seven days ago) is the "domingo de ramos" everyone buys a hand made bouquet of palm leaves, actually there is a campain to stop the use of this palm tree (is a very special one, i forgot the name) because is a species in danger.
I don't know very much about what all catholics do, here in thursday catholics usually do the visit of the monuments, you go to seven different churches and pray, if you live in a small town with only one church (like my dad when he was a kid) you enter the church and exit it seven times!
there is a mass sevice at midnight, but im not sure if is on thursday or friday.
The friday almost everyone close their business, especially at three o'clock, which is the time when supposdly jesus died, at that point, no church play their bells, everyone use a "matraca" wich is like a device to make an annoying sound, very aprecciated around here, (i hate it though).
The other days you just pray a lot if you are a true catholic or just spend the free time playing games (like me and my brother )
|2004-04-11, 14:38
|Link #10
Evangelist of the Kazoo
Join Date: Apr 2003
Location: AnimeSuki Forums
|2004-04-11, 15:30
|Link #13
Lateral G's
I think I'll celebrate Easter by having a nicely cooked tender rabbit, a crossant, some steamed veggies, maybe a side of Duck, Mash potatoes, Cranberry Relish, and a good 'ol Captain Morgans and Coke *aka 'CapnCoke*
|2004-04-11, 15:54
|Link #15
Join Date: Jul 2003
Location: Austin, TX
Age: 36
|2004-04-11, 16:04
|Link #16
Tekkaman Blade!
Join Date: Feb 2004
Location: Bakersfield, CA, USA,
Age: 31
Hmm. My church was so crowded that they had to open the doors to the main chapel and set up chairs outside those in order to accomidate everyone [did I spell that right?]. This was not including the extra chairs set up behind the pews. The choir's chairs were empty, but we couldn't use those for some reason...
I sat outside in hopes that I could open up a spot inside for someone who comes to church rarely. I saw over 50 people leave because it was so packed. Sort of sad...
|2004-04-11, 16:40
|Link #18
Tekkaman Blade!
Join Date: Feb 2004
Location: Bakersfield, CA, USA,
Age: 31
My sleep cycle is still off due to an overnight LAN party [from 10p - 6a]. Joy...[/groggy]
|2004-04-11, 17:37
|Link #19
Join Date: Jul 2003
Location: Austin, TX
Age: 36
Sounds like my psychology class whenever there is an exam
|Thread Tools


text:
- Inside Athletics
- Tickets
- Fan Zone
- Media Zone
- Social
- Shop
- E Fund
GREENEVILLE, Tenn. (September 6, 2006) - The Volley Bucs tuned up for their weekend tournament by dispatching Tusculum in three quick games 30-16, 30-26, 30-25 Wednesday evening in non-conference action at Pioneer Arena on the Tusculum College campus.
The Lady Bucs (5-2) rolled out to 9-1 lead in the opening game, and cruised to the 30-16 final. Senior Crystal Palmer (
14 total Pioneer errors helped ETSU to the four point game two victory, as Tusculum committed one ball handling error, six attack errors and a whopping seven service errors in the second game alone. Kiselich contributed four more kills, while senior Sarah Buhr (
The Pioneers (4-3) stayed close in game three, until three consecutive service aces from senior Jennifer Sartor (
In addition to her 11 kills, Kiselich finished the night with a .526 hitting percentage, reaching her kill total in 19 total attacks, while committing just one error.
The Lady Bucs return to action Friday evening in their opening game of the Lady Bucs Volleyball Classic presented by Best Western against Furman at The tournament begins at with